#fast track

Plasma from recovered patients recently received a controversial FDA emergency use authorization as a potential treatment for COVID-19.

Janssen has entered into a collaboration with Achillion to develop and commercialize hepatitis C treatments.

FDA has granted fast-track status to Galmed Pharmaceuticals’ aramchol, an investigatory treatment for non-alcoholic steatohepatitis (NASH).

The FDA has sped up the development and approval process for promising new hepatitis C therapies from three different companies.

ACH-3102, a hepatitis C drug under development by Achillion Pharmaceuticals, has received Fast Track status from the FDA, according to an...

The FDA has assigned the Fast Track designation to Achillion Pharmaceuticals, Inc.’s ACH-1625